The Oncology Institute (TOI) Q4 2024 earnings summary

Executive summary

• Revenue grew 21.3% year-over-year in 2024, reaching $393M, driven by value-based patient services and dispensary growth, though patient services declined 4% due to a lost contract.

• Q4 2024 revenue was $100.3M, up 17% year-over-year, with dispensary revenue up 73% annually and new contracts covering over 200,000 lives.

• Operational improvements and cost controls led to a 12% reduction in SG&A in Q4 and improved cash flow, with two consecutive quarters of positive cash from operations.

• Net loss for 2024 was $64.7M, improved by $18.4M year-over-year; Q4 net loss was $13.2M, improved from $18.8M in Q4 2023.

• Balance sheet strengthened through $20M debt paydown and a $16.5M equity raise, reducing debt from $110M to $86M.

Financial highlights

• Q4 2024 gross profit: $15M, up 1.8% year-over-year; full-year gross profit: $54M, down 9.4% due to lower drug margins and higher clinical payroll.

• Q4 adjusted EBITDA: -$7.8M, impacted by a $3M one-time fee-for-service revenue reduction; full-year adjusted EBITDA: -$35.7M.

• Cash and cash equivalents at year-end: $49.7M–$50M, up $2.3M from Q3.

• Basic and diluted loss per share for Q4 2024 was $(0.14), improved from $(0.21) in Q4 2023.

• Full-year operating cash flow was $(26.5)M, improved from $(36.3)M in 2023.

Outlook and guidance

• 2025 revenue guidance: $460M–$480M (17–22% growth); gross profit: $73M–$82M; adjusted EBITDA: -$8M to -$17M; free cash flow: -$12M to -$21M.

• Profitability and cash flow break-even targeted in Q4 2025.

• Q1 2025 adjusted EBITDA expected at -$5M to -$6M due to seasonal drug price increases and lower encounter volumes.

• Growth driven by new capitation contracts, dispensary expansion, and organic growth, especially in Florida.

• Guidance assumes a largely reopened market and does not account for unanticipated business developments.